Solid Tumor Therapeutics

实体肿瘤治疗 实体瘤治疗学（STT）的总体目标是开发针对肿瘤的新疗法和策略。 治疗非血液学恶性肿瘤，并推进所需的诊断和生物标志物工具， 个性化使用。因此，短期信托基金直接支持千年挑战公司的使命、愿景和战略优先事项， 优先利用MCC的发现，以最大限度地提高我们的能力， 每个病人的个人资料STT的59名成员来自不同的学科，但却团结在一起。 他们在实体肿瘤生物学和治疗方面的共同研究兴趣。考虑到这一点， 16个部门和4所学校。2017年，项目成员在癌症治疗方面总共花费了2230万美元（直接成本）。 经费1300万美元（直接成本）是同行评审资金，其中600万美元（46%）来自NCI，390万美元（30%）来自 来自其他NIH来源，300万美元（23%）来自其他同行评审机构。在项目期间， 成员撰写了1662篇与癌症相关的出版物，其中255篇（15%）是计划内的，295篇（18%） 是跨项目的，485（29%）与其他NCI指定的癌症研究者合作 中心. STT成员还领导了64项早期阶段的药物启动试验（IIT），其中包括20项 MCC的科学发现通过26个IIT应用于临床，比2008年至2010年期间的2个IIT增加了13倍。 2012. STT治疗IIT的累积增加了218%，从223（2008-2012）增加到709（2013-2017）。STT 具体目标是：1）确定肿瘤的脆弱性，机制和靶向改变; 2）开发新的 3）开发新的技术来检测肿瘤和定义肿瘤 地理、微环境和可利用的代谢和信号传导缺陷;以及4）建立临床 新疗法和基因组驱动的治疗策略的好处。贯穿各领域的主题是：A）免疫 肿瘤学; B）癌症干细胞，和C）患者特异性精确治疗。STT由医学博士Ezra Cohen共同领导， 头颈癌和免疫肿瘤学发现的临床应用方面的专家;和杰里米 里奇，医学博士，MHS，MBA，其职业生涯一直专注于癌症干细胞和脑肿瘤。他们的高度融合 努力促进STT杰出研究人员之间的合作，他们是各自领域的领导者， 卓越的生产力记录。

SOLID TUMOR THERAPEUTICS ABSTRACT The overall goal of Solid Tumor Therapeutics (STT) is to develop novel therapeutics and strategies for the treatment of non-hematologic malignancies and to advance the diagnostic and biomarker tools needed to individualize their use. As a result, STT directly supports the mission, vision, and strategic priorities of MCC, which has prioritized exploiting MCC’s discoveries to maximize our ability to tailor cancer care plans based on each patient’s personal profile. The 59 members of STT come from diverse disciplines but are joined together by their shared research interest in solid tumor biology and treatment. Reflecting this, members are drawn from 16 departments and 4 schools. In 2017, program members had a total of $22.3M (direct costs) in cancer-focused funding. $13.0M (direct costs) is peer-reviewed funding, of which $6.0M (46%) was from NCI, $3.9M (30%) was from other NIH sources, and $3.0M (23%) was from other peer-reviewed agencies. During the project period, members authored 1662 cancer-relevant publications, of which 255 (15%) were intra-programmatic, 295 (18%) were inter-programmatic, and 485 (29%) were collaborative with investigators from other NCI-designated cancer centers. STT members also led 64 early phase investigator-initiated trials (IITs), which include translation of 20 of MCC’s scientific discoveries to the clinic through 26 IITs, a 13-fold increase over 2 such IITs between 2008- 2012. Accrual to STT treatment IITs increased by 218%, from 223 (2008-2012) to 709 (2013-2017). STT’s specific aims are to: 1) Identify tumor vulnerabilities, mechanisms, and targetable alterations; 2) Develop new classes of therapeutics and delivery systems; 3) Develop novel technologies to detect tumors and define tumor geography, microenvironment, and exploitable metabolic and signaling defects; and 4) Establish the clinical benefit of novel therapeutics and genome-driven treatment strategies. The cross-cutting themes are: A) Immune Oncology; B) Cancer Stem Cells, and C) Patient-specific Precision Therapy. STT is co-led by Ezra Cohen, MD, an expert in head and neck cancer and the clinical application of immune oncology discoveries; and Jeremy Rich, MD, MHS, MBA, whose career has focused on cancer stem cells and brain tumors. Their highly integrated efforts foster collaboration among the outstanding investigators in STT, who are leaders in their fields and have track records of extraordinary productivity.